buy toast 10 pro cheapest corel draw best price quicken 2007 premier buy audition 2.0 buy microsoft office 2013 starter price of adobe flash professional buy roxio creator 7.5 discount bento 2 family pack purchase reason 4 price of office 2007 standard best price dragon naturally speaking buy revit architecture 2010 discount adobe audition 3 buy camtasia studio software best price photoimpact pro best price eset security buy aperture 1 cheap adobe photoshop elements 6 mac best price microsoft office excel 2007 best price aperture buy iwork 08 cheap buy office 2008 for mac business edition download autodesk autocad civil 3d 2015 cost of autodesk autocad plant 3d 2015 buy dreamweaver cs4 uk microsoft office 2013 academic student discount price of adobe photoshop 6 buy windows 7 online uk buy microsoft office 2013 home buy indesign 2.0

Cancer Prevention Research

Mon, Nov 25, 2013

Oral Cancer News

 

Clinical and biochemical studies support smokeless tobacco’s carcinogenic potential in the human oral cavity

 
Source: American Association of Cancer Research
Published: November 9, 2013
By: Susan R. Mallery, Meng Tong, Gregory C. Michaels, Amber R. Kiyani, and Stephen S. Hecht

 

Abstract

In 2007, International Agency for Cancer Research presented compelling evidence that linked smokeless tobacco use to the development of human oral cancer. While these findings imply vigorous local carcinogen metabolism, little is known regarding levels and distribution of Phase I, II and drug egress enzymes in human oral mucosa. In the study presented here, we integrated clinical data, imaging and histopathologic analyses of an oral squamous cell carcinoma that arose at the site of smokeless tobacco quid placement in a patient. Immunoblot and immunohistochemical (IHC) analyses were employed to identify tumor and normal human oral mucosal smokeless tobacco-associated metabolic activation and detoxification enzymes. Human oral epithelium contains every known Phase I enzyme associated with nitrosamine oxidative bioactivation with ~2 fold inter-donor differences in protein levels. Previous studies have confirmed ~3.5 fold inter-donor variations in intraepithelial Phase II enzymes. Unlike the superficially located enzymes in non-replicating esophageal surface epithelium, IHC studies confirmed oral mucosal nitrosamine metabolizing enzymes reside in the basilar and suprabasilar region which notably is the site of ongoing keratinocyte DNA replication. Clearly, variations in product composition, nitrosamine metabolism and exposure duration will modulate clinical outcomes. The data presented here form a coherent picture consistent with the abundant experimental data that links tobacco-specific nitrosamines to human oral cancer.

 

* This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

 

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.